Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05396677
Other study ID # 21-07-024
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2022
Est. completion date December 2022

Study information

Verified date May 2022
Source University of Guelph
Contact Savannah Yerman, M.A.
Phone 5197311004
Email syerman@uoguelph.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the effects of acetaminophen on behavioral, physiological, and self-report fear responses.


Description:

As acetaminophen blunts the experience of physical, social, and empathic pain, it is important to investigate whether there are other aversive states that the drug also provides relief from. If there are others, this may suggest overlapping mechanisms involved in these affective evaluations, all of which are interrupted by acetaminophen. The emotion of fear is aversive, yet it is distinct from both physical and social pain. The present study will investigate the effects of acetaminophen on the subjective experience of fear as well as its behavioral outcomes. While blocking adaptive behavioral responses to fear could potentially be problematic in some dangerous situations, it may also be helpful for those with anxiety-related disorders. If individuals on acetaminophen can step farther away from safety on a virtual plank 80 stories above the ground, then perhaps acetaminophen can allow anxious individuals to step farther from their comfort zone in real life. Importantly, if acetaminophen blunts the fear response, this would mean that the drug blocks aversive feelings beyond emotional and physical pain. The extent of its effects will warrant further investigation for a greater understanding of emotional evaluations.


Recruitment information / eligibility

Status Recruiting
Enrollment 266
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Literate - Speaks English - Does not have any risk factors associated with acetaminophen (history of liver or kidney disease, taking other products with acetaminophen, has any allergies to acetaminophen, taking blood-thinning medications, drinks more than 12 alcoholic drinks per week for females, or more than 15 alcoholic drinks per week for males, are/ could be pregnant) - Has taken acetaminophen in the past without any adverse reactions - Is not diabetic - Did not have anything to eat within three hours of study time - Did not have any acetaminophen or alcohol in the 48 hours prior to study - Has never had an adverse reaction to virtual reality before, such as headaches or nausea Exclusion Criteria: - Younger than 18 - Non-literate - Does not speak English - Has at least one risk factor associated with acetaminophen (history of liver or kidney disease, taking other products with acetaminophen, has any allergies to acetaminophen, taking blood-thinning medications, drinks more than 12 alcoholic drinks per week for females, or more than 15 alcoholic drinks per week for males, are/ could be pregnant) - Has never taken acetaminophen before - Diabetic - Had something to eat within three hours of scheduled study time - Has had acetaminophen or alcohol in the past 48 hours - Has had an adverse reaction to virtual reality in the past, such as headaches or nausea

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acetaminophen
2 x 500 mg acetaminophen (one time)
Other:
Placebo
2 x 500 mg microcrystalline cellulose (one time)

Locations

Country Name City State
Canada University of Guelph Guelph Ontario

Sponsors (2)

Lead Sponsor Collaborator
University of Guelph Natural Sciences and Engineering Research Council, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Walking speed on plank in virtual reality Farthest distance reached on plank / time to get there 1 hour after taking acetaminophen or placebo
Primary Distance walked on plank (Unless there are ceiling effects in which >90% of people make it to the end.) Measured in cm walked on a 2 m wooden plank before deciding to turn around and walk back. 1 hour after taking acetaminophen or placebo
Primary Proportion of time spent looking down at the plank We will record what participants see in virtual reality while doing the plank walk, and then code the footage to calculate the proportion of time on the plank participants spent looking down at the plank (indicating more anxiety about falling off). 1 hour after taking acetaminophen or placebo
Primary Decision on whether to do the plank walk again with virtual spiders After doing the plank walk, participants will be offered an optional second chance to try the same plank walk again but this time with virtual giant spiders around them. 1 hour after taking acetaminophen or placebo
Primary Verbal Self-Report Fear While participants are in virtual reality, we will ask them to rate their fear verbally twice, once when they first step onto the plank, and once when they have changed direction (during which the plank tends to shake). They will answer from 0 (no fear or anxiety) to 10 (extreme fear or anxiety). For those who decide to do the plank walk again with virtual giant spiders, they will also rate their self-reported fear in the same manner twice, once when the spiders first appear, and once when they are on their way back to the virtual elevator while surrounded by giant spiders. 1 hour after taking acetaminophen or placebo
Primary Written Self-Report Fear After taking off the headset, participants will answer two survey questions. The first is, "How scary do you think most people would agree the act of walking on a virtual plank is?" They will answer on an 11-point scale (0 = Not at all scary, 5 = Moderately scary, 10 = Extremely scary). They will also be asked "How fearful, scared, nervous, or anxious did you personally feel when walking on the virtual plank?" (0 = Not at all fearful or anxious, 5 = Moderately fearful or anxious, 10 = Extremely fearful or anxious). Those who choose to do the second optional plank walk with virtual spiders will answer the same questions about that experience afterwards. 1 hour after taking acetaminophen or placebo
Primary Heart rate Average heart rate while on the plank walk, measured with a Polar Verity Sense optical heart rate sensor on forearm. 1 hour after taking acetaminophen or placebo
Secondary Time to take first step onto plank Number of seconds it takes participants to leave the virtual elevator for the plank overlooking a virtual 80-story drop. 1 hour after taking acetaminophen or placebo
Secondary Speed towards virtual elevator after turning around on plank, Amount of time it takes them to make it back to the starting point after turning around on the plank. It is not clear whether someone who walks faster would be doing so to get back to the feeling safety quicker or because they are less cautious due to less fear, and so this is a secondary measure. 1 hour after taking acetaminophen or placebo
Secondary Time before needing a break or quitting the virtual reality plank walk (Unless there are ceiling effects in which >90% of participants do not quit early or need a break). Amount of time before a participant takes their headset off early, to quit or for a break, due to being overwhelmed. 1 hour after taking acetaminophen or placebo
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05534490 - Surgery and Functionality in Older Adults N/A
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Completed NCT04127097 - The Effect of Watching Cartoons During Treatment on Children's Anxiety and Fear Levels N/A
Recruiting NCT04039243 - Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study N/A
Completed NCT03966391 - Effectiveness of CARD for Improving School-Based Immunizations N/A
Completed NCT05955755 - The Effect of Butterfly Vacuum Blood Collection Set and Standard Vacutanier Needle on the Level of Pain and Fear N/A
Completed NCT05191407 - Fear and Anxiety Level in Dental Patients During the COVID-19 Pandemic
Terminated NCT03966300 - Improving the School Vaccination Experience: What CARDs Are You Going to Play? N/A
Completed NCT06112600 - The Impact of Virtual Reality and Kaleidoscope in Children During Vaccination N/A
Completed NCT06012877 - Evaluation of the "Health Friendly" Program to Reduce Children's Fear of the Healthcare Environment. N/A
Completed NCT05789810 - Manual Pressure and ShotBlocker to Reduce Needle-Related Pain and Fear N/A
Not yet recruiting NCT05494684 - Effectiveness of Multisensoral Nature-based Intervention in Hospitalized Children During Venous Blood Sampling N/A
Completed NCT04577612 - A Randomized Controlled Test of the Effects of CHI-554 on Fear. Phase 2
Completed NCT04040036 - Effects of Virtual Reality on Pain, Fear and Anxiety During Blood Draw in Children Aged 5-12 Years Old N/A
Active, not recruiting NCT03993509 - Effect of rTMS on Anxiety N/A
Completed NCT04259463 - The Influence of Sedation and General Anesthesia to Patients' Psycho-emotional State Undergoing Wisdom Teeth Extraction
Completed NCT01398007 - Use of the Camouflage Syringe to Reduce Dental Anxiety and Fear in Children Phase 2
Completed NCT05161416 - The Effects of Cartoon Watching and Bubble Blowing as Distraction Methods During Venipuncture on Pain, Anxiety, and Fear in Children Aged 6-8 Years N/A
Completed NCT06090175 - The Effect of Using Projector Kaleidoscope and Matching Card on Children's Fear and Physiological Parameters N/A
Recruiting NCT05543876 - The Effect of Video Watching With Virtual Reality Glasses on Pain and Fear of Children N/A